OTLC
Oncotelic Therapeutics, Inc.Company Information
- Company Name
- Oncotelic Therapeutics, Inc.
- CIK
- CIK0000908259
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OTLC: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OTLC
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-01
- Last sale
- —
- Shares purchased (TTM)
- 718,759
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2020-03-31
- Institutional shares owned
- 10,934
- Shares outstanding
- 88,152,403
- Ownership
- 0.01%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -40.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | - | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | - | ||||||
| Cash | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Restricted Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets | - | - | - | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Other | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Goodwill | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | ||||||
| Equity Securities F V N I Noncurrent | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Investment Owned At Fair Value | 388 | 388 | 388 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | ||||||
| Assets | 395 | 394 | 393 | 28 | 27 | 27 | 27 | 27 | 30 | 30 | 30 | 30 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | ||||||
| Business Combination Contingent Consideration Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Derivative Liabilities Current | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 8 | - | ||||||
| Liabilities Current | 18 | 18 | 18 | 20 | 19 | 19 | 19 | 16 | 16 | 17 | 17 | 17 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Liabilities Noncurrent | - | - | - | - | - | - | - | 2 | - | 2 | - | - | ||||||
| Convertible Debt Noncurrent | 2 | 2 | - | - | - | - | - | - | - | - | 2 | - | ||||||
| Deferred Income Tax Liabilities | 112 | 112 | 112 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 131 | 132 | 131 | 20 | 19 | 19 | 19 | 19 | 18 | 19 | 18 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Additional Paid In Capital | 51 | 50 | 47 | 44 | 42 | 42 | 42 | 42 | 42 | 42 | 42 | 41 | ||||||
| Retained Earnings Accumulated Deficit | 209 | 209 | 211 | -39 | -38 | -38 | -38 | -37 | -34 | -34 | -34 | -33 | ||||||
| Stockholders Equity | 265 | 262 | 263 | 8 | 7 | 8 | 7 | 9 | 12 | 12 | 12 | 12 | ||||||
| Minority Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | ||||||
| Liabilities And Stockholders Equity | 395 | 394 | 393 | 28 | 27 | 27 | 27 | 27 | 30 | 30 | 30 | 30 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | - | - | - | 0.01 | - | - | 0.01 | - | - | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | - | - | - | 15 | - | - | 15 | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | 0 | - | - | 0 | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | 0 | - | - | 0 | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 750 | 750 | 750 | 750 | 750 | 750 | 750 | 750 | 750 | 750 | 750 | 750 | ||||||
| Common Stock Shares Issued | 457 | 444 | 443 | 439 | 408 | 408 | 407 | 407 | 407 | 400 | 399 | 398 | ||||||
| Shares Outstanding | 457 | 444 | 443 | 439 | 408 | 408 | 407 | 407 | 407 | 400 | 399 | 398 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOncotelic Therapeutics, Inc. (OTLC) — SEC Financial Statements & Analysis
Oncotelic Therapeutics, Inc. (OTLC) is a pharmaceutical preparations company, incorporated in DE. Oncotelic Therapeutics, Inc. trades on OTC as: OTLC. Oncotelic Therapeutics, Inc. (OTLC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Oncotelic Therapeutics, Inc. carries a market cap of $17.90M, a P/E ratio of 0.07x, a P/B ratio of 0.07x, a P/S ratio of 71.58x, an enterprise value of $19.56M, and an EV/EBITDA multiple of -3.42x. On profitability, it posts an operating margin of -2286.59%, a net margin of 99024.99%, a Return on Equity (ROE) of 182.06%, a Return on Assets (ROA) of 117.49%, and a Return on Invested Capital (ROIC) of -4.18%. Per share, it reports EPS of $0.55, diluted EPS of $0.53, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -6515.45% year-over-year, and EPS growth of -5954.85% year-over-year. On the balance sheet, it maintains a current ratio of 0.08x, a quick ratio of 0.01x, working capital of $-16.45M, a debt-to-equity ratio of 0.50x, a debt ratio of 0.33, an interest coverage ratio of -17.96x, free cash flow of $-1.52M (TTM), and net debt of $1.67M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.90M
- P/E TTM
- 0.07x
- EPS TTM
- $0.55
- P/B TTM
- 0.07x
- ROE TTM
- 182.06%
- ROA TTM
- 117.49%
- Debt To Equity
- 0.50x
- Free Cash Flow TTM
- $-1.52M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Oncotelic Therapeutics, Inc. in?
Oncotelic Therapeutics, Inc. (OTLC) operates in the Pharmaceutical Preparations industry.
What exchange does OTLC trade on?
Oncotelic Therapeutics, Inc. (OTLC) trades on the OTC.
Where is Oncotelic Therapeutics, Inc. incorporated?
Oncotelic Therapeutics, Inc. is incorporated in DE.
When was Oncotelic Therapeutics, Inc. (OTLC)'s most recent SEC filing?
Oncotelic Therapeutics, Inc. (OTLC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is OTLC's market cap?
Oncotelic Therapeutics, Inc. (OTLC) has a market capitalization of $17.90M as of 2026-06-30.
What is OTLC's P/E ratio?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month P/E ratio is 0.07x as of 2026-06-30.
What is OTLC's EPS (earnings per share)?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month EPS is $0.55 as of 2026-06-30.
What is OTLC's ROE (return on equity)?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month Return on Equity (ROE) is 182.06% as of 2026-06-30.
What is OTLC's ROA (return on assets)?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month Return on Assets (ROA) is 117.49% as of 2026-06-30.
What is OTLC's ROIC (return on invested capital)?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month Return on Invested Capital (ROIC) is -4.18% as of 2026-06-30.
What is OTLC's EV/EBITDA?
Oncotelic Therapeutics, Inc. (OTLC)'s trailing twelve month EV/EBITDA is -3.42x as of 2026-06-30.